GlassScriptPhysician profile
Mimi N Ton
NPI 1033178355
$1,443.85
in general payments reported to CMS, 2019-2025
30 companies · $397 in 2025
The $397 reported for 2025 was more than what a typical Pediatric Gastroenterology provider received nationally (typical 2025 total: $195).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $140 · 2020: $76.89 · 2021: $68.48 · 2022: $107 · 2023: $298 · 2024: $357 · 2025: $397.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,052.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,051.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mirum Pharmaceuticals, INC. | $322.79 | 2024-2025 | Livmarli, Cholbam |
| Abbvie INC. | $119.65 | 2019-2021 | |
| Biomarin Pharmaceutical INC. | $107.68 | 2024-2025 | Brineura |
| Coloplast Corp | $96.87 | 2023 | Peristeen |
| Ipsen Biopharmaceuticals, INC | $74.35 | 2023-2025 | Bylvay |
| Glaxosmithkline, LLC. | $63.89 | 2022-2025 | Nucala |
| Travere Therapeutics, INC. | $60.02 | 2019-2022 | |
| Genzyme Corporation | $58.13 | 2023-2025 | |
| Janssen Biotech, INC. | $48.57 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $39.36 | 2021-2025 | Eohilia, Gattex |
| Alexion Pharmaceuticals, INC. | $36.43 | 2024-2025 | Strensiq |
| Kyowa Kirin, INC. | $35.33 | 2024-2025 | Crysvita |
| Amgen INC. | $34.75 | 2023 | Amjevita, Avsola |
| Organon LLC | $31.70 | 2024 | |
| Sandoz INC. | $31.41 | 2023 | Hyrimoz |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tolmar, INC. | $30.67 | 2023-2025 | Fensolvi |
| Nestle Healthcare Nutrition INC. | $29.23 | 2021 | |
| Albireo Pharma, INC. | $26.10 | 2022-2023 | Bylvay |
| Kadmon Pharmaceuticals LLC | $23.09 | 2019 | |
| Endo USA, INC. | $19.25 | 2025 | Supprelin |
| Azurity Pharmaceuticals, INC. | $18.19 | 2024 | Triptodur |
| Xeris Pharmaceuticals, INC. | $16.80 | 2024 | Gvoke Hypopen |
| Neurocrine Biosciences, INC. | $16.37 | 2025 | |
| Becton, Dickinson and Company | $15.79 | 2019 | |
| Ucb, INC. | $15.75 | 2023 | Fintepla |
| Insulet Corporation | $14.81 | 2024 | Omnipod |
| Celgene Corporation | $14.74 | 2022 | |
| Neurelis, INC. | $14.52 | 2021 | |
| Cumberland Pharmaceuticals, INC. | $14.48 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $13.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mimi Ton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.